Stay updated on Acalabrutinib vs Ibrutinib in CLL Clinical Trial
Sign up to get notified when there's something new on the Acalabrutinib vs Ibrutinib in CLL Clinical Trial page.

Latest updates to the Acalabrutinib vs Ibrutinib in CLL Clinical Trial page
- CheckyesterdayChange DetectedThe study now lists 130 locations and has removed Istanbul, Türkiye. A link to the Genetic and Rare Diseases Information Center is added, and the term B-cell chronic lymphocytic leukemia is included.SummaryDifference0.3%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3 as part of the page's revision history.SummaryDifference0.0%

- Check23 days agoChange DetectedAdded Revision: v3.4.3; removed Revision: v3.4.2.SummaryDifference0.0%

- Check51 days agoChange DetectedA minor site version update is shown (Revision: v3.4.2) and the funding-status notice has been removed as part of routine maintenance. These changes do not affect the study content or its presentation, and to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check58 days agoChange DetectedAdded a site-wide notice about the lapse in government funding and the NIH open status, plus a version update to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check65 days agoChange DetectedAdded a Show glossary option and new QC-related metadata (Last Update Submitted that Met QC Criteria, Last Update Posted, Revision: v3.4.0). Removed or deprecated older QC fields (Last Update Submitted that met QC Criteria, Last Update Posted (Estimated)), No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.1%

Stay in the know with updates to Acalabrutinib vs Ibrutinib in CLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Acalabrutinib vs Ibrutinib in CLL Clinical Trial page.